Mechanism of Production of Inflammatory Mediators Flashcards

1
Q

What is inflammation?

A
  • Inflammation is the initial response of the innate immune system to infection and injury
  • Conserved across all metazoan organisms
  • Non-specific cytotoxic response → kills pathogen infected cells and promotes healing and recovery
  • Response also kills healthy cells, but collateral damage is acceptable because it is getting rid of the pathogen
  • When excessive or dysregulated however, it contributes to disease.
  • Can be acute or chronic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is sterile inflammation?

A
  • Inflammation in the absence of a pathogen
  • Driven by endogenous molecules – DAMPs
  • Normally retained inside cells, but can be released following injury → so shielded from the immune system until after injury.
  • May resolve the initial insult, but is often a self-amplifying loop promoting disease
  • Has been found to worsen non-communicable diseases (disease that occur in the absence of a pathogen) such as CVD, cancer etc…
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the cellular effectors of innate immunity?

A

Circulating:
• Neutrophils → most abundant granulocyte. First innate immune cells to migrate to the area of inflammation
• Monocytes → largest. Replenish tissue macrophages
• Basophils → least common. Secrete histamine
• Eosinophils → important for parasites
• NK cells → innate-like lymphocytes. Analogous to the cytotoxic T cell.

Tissue:
• Macrophage → major phagocyte in normal tissue
• Microglia (brain specific) → resident macrophages of the brain and spinal cord, and act as the main form of active immune defence in the CNS.
• Mast cell → tissue basophil
• DC → phagocytic, but their main function is as an APC. Conventional DC main function is to phagocytose microbes to present antigen to T cells and induce an adaptive immune response. They also produce cytokines. Are seen as a bridge between the innate and adaptive immune system. Plasmacytoid DCs are the major produces of antiviral IFNs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is a cytokine and what are the 3 cytokine classes?

A
  • Secreted pro or anti inflammatory mediators
  • Overproduction or dysregulation is a major contributor to disease
  • Around 25kDa
  • Usually secreted in response to an activating stimulus
  • Can act in autocrine, paracrine and endocrine manners
  • Activation of PRRs induces the production of cytokines that activate the cellular arm of the innate immune system

Classes:
• Lymphokines → produced by lymphocytes, coordinate T cell responses
• ILs → produced mainly by leukocytes. Multiple inflammatory and immunomodulatory effects
• Chemokines → induce chemotaxis. Required for recruitment of immune cells to infected/injured tissue.

• The cytokines secreted by macrophages and DCs in response to PRR activation include IL-1B, IL-6, IL-12, TNFa and the chemokine CXCL8 (formerly IL-8)

The IL-1 family (main family involved in neuroinflammation):
• Contains 11 members, notably IL-1a, IL-1B and IL18
• Most produced as inactive pro-proteins that are cleaved to produce the mature cytokine → Il-1B and IL-18 produced by macrophages are cleaved by caspase 1
• IL-1 family receptors have extracellular regions composed of Ig-like domains that signal as dimers through TIR domains in their cytoplasma tails.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are TLRs

A
  • One of the best characterized PRRs
  • Toll was first discovered in Drosophila, whereby its signaling induces expression of host defence mechanisms including the production of antimicrobial peptides such as Drosomycin.
  • Production of antimicrobial peptides seem to be the earliest form of defense against infection, so receptors that signal for this have claim on being the earliest receptors dedicated to defense against infection.
  • Cloning of the human homologue was peformed by Medzhitov, Preston-Hyrlburt and Janeway – but no nobel prize!
  • There are 10 expressed TLR genes in humans
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe TLR structure and function

A

• Sensors for microbes in the extracellular space
− Some are cell-surface receptors, and some are endosomal
− The ones that are intracellular detect pathogens that have been phagocytosed
• Single-pass transmembrane receptors comprised of 18-25 leucine-rich repeats that create a horseshoe-shaped protein scaffold for ligand binding on both the concave and convex surface.
• Activated when binding of a ligand induces them to form dimers → all TLRs have a TIR domain in their cytoplasmic tail with interacts with other TIR domains
• Activation often leads to the production of NFkB:
− Nuclear Factor Kappa-light-chain-enhancer of activated B cells (actually present everywhere)
− p65/p50 dimer retained inactive by Inhibitor of NFkB (IkB)
− Dissociation from IkB occurs after cellular stress, cytokines, TLR activation → allowing it to translocate to the nucleus.
• Activation may also result in production of interferon regulatory factor and members of the AP-1 family such as c-Jun through a signaling pathway involving MAPK. NFkB and AP-1 induce pro-inflammatory cytokines, whereas IRFs produce antiviral type 1 interferons.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the signalling pathway that results in NFkB activation from TLR recognition.

A
  1. TLR signaling activated by the ligand-induced dimerization of two TLR ectodomains, which brings their cytoplasmic TIR domains close together. This allows them to interact with the TIR domains of cytoplasmic adaptor molecules, such as:
    • MyD88 (myeloid differentiation factor 88)
    • MAL (MyD88 adaptor-like)
    • TRIF (TIR domain containing adaptor inducing IFNb)
    • TRAM (TRIF related adaptor molecule)
  2. Adaptors recruit IRAK-1 & IRAK-4, which activate the E3 ubiquitin ligase TRAF-6
    • Catalyses attachment of ubiquitin to lysine 63 of TRAF-6
    • NEMO is also polyubiquitinated
  3. Ubiquitin usually targets protein for degradation, but can also have a signaling role – here it serves as a scaffold that allows recruitment of TAK1.
  4. TAK1 activates IKK by phosphorylation of its beta subunit.
  5. IKK phosphorylates IkB at serines 32 and 36. This leads to polyubiquitination of IkB at lysine 48.
  6. IkB is subsequently degraded by the proteasome.
  7. NFkB is free to migrate to the nuclease and initiate transcription of pro-inflammatory genes, eg) IL and TNF cytokines.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the role of ubiquitination (inc. the proteasome) in regulating inflammatory gene expression.

A

• Ubiquitin is a small (76aa) protein
• The proteasome is a large protein complex that recognizes and degrades ubiquitinated proteins
− Typical proteasome is a 20S catalytic core and two 19S regulatory caps.
− The core is a large cylindrical complex of 28 subunits, arranged in 4 stacked rings of 7 subunits.it is hollow, lined by the active sites of the proteolytic subunits.
− Ubiquitination targets proteins to the 19S cap
− ATPases control the opening of the 20S core chamber, regulating protein entry.
− Inside, the protein is broken down into short peptides which are released into the cytosol

So, protein ubiquitination regulates inflammatory gene expression via multiple ways:
• Scaffold on TRAF-6 for recruitment of TAK1 and subsequent activation of IKK
• Targets IkB for degradation, enabling NFkB to migrate to the nucleus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the NOD and NLRP cytoplasmic PRRs

A

• Mainly of the NLR family (Nucleotide-binding domain and leucine-rich repeat receptor)
• 23 members in humans
• Subfamilies can be distinguished on the basis of protein domains in their amino terminus:
− NOD → caspase recruitment domain (CARD) .
− CARD can dimerise with CARD domains on other proteins, and is involved in many intracellular pathways, including those leading to apoptosis.
− Recognise fragments of bacterial cell wall peptidoglycans → recruits CARD-containing RIPK → activates TAK1 → activates IKK → phosphorylates IkB → activates NFkB → inflammatory cytokine production.

− NLRP → pyrin domain
− Humans have 14 NLRs – best characterized is NLRP3 (or cryopyrin) which is an important sensor of cellular damage or stress.
− NLRP3 has a tripartite structure:
− PAMP/DAMP sensing C-terminal LRR
− Central nucleotide binding domain
− N-terminal effector domain (pyrin)
1. Efflux of K+ ions from damaged cells induces dissociation of the accessory proteins from NLRP3
2. Allows activation of the pyrin domain with that of the adaptor molecule apoptosis-associated speck-like protein with a caspase recruitment domain (ASC)
3. The CARD of ASC binds to the CARD domain of pro-caspase 1, facilitating production of activate caspase 1 molecule = the inflammasome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is meant by the priming step of IL-1 production?

A
  • Acute brain injury such as stroke can be considered a sterile insult that induces an inflammatory response that can further exacerbate the initial injury.
  • In sterile injuries, IL-1a and IL-1B have been identified as key mediators of the damaging inflammatory response
  • Both produced as precursors by cells of the innate immune system in respone to PAMPs and DAMPs activating TLRs to regulate NFkB
  • PAMP induced expression is the first stage in IL-1 production, and is known as the priming step.
  • The precursors pro-IL1a and pro-IL1B remain associated with a primed cell until the second stage of IL-1 production, when the primed cell encounters a further stimulus → this can be another PAMP, or a DAMP in sterile inflammation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe IL-1a activation

A
  • Pro-IL-1a is biologically active and freely soluble
  • Any events leading to membrane rupture or death of cells expressing pro-IL1a could result in its release and a pro-inflammatory response.
  • In contrast to pro-IL-1B, pro-IL1-a can be actively transported to the nucleus of the cell, and Brough reported that this retention after cell necrosis limits IL-1a release and could potentially dampen sterile inflammatory responses.
  • Although doesn’t have to be cleaved to be actived, has to be cleaved to be released → by the activity of calcium-dependent calpain proteases – these may be membrane associated, such that mature IL-1a may be formed upon release from the cell.
  • Although pro-IL1a is not a substrate for caspase 1, IL-1a release is inhibited in macrophages isolated from capase 1 and NLRP3 KO mice in response to some DAMPs.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe IL-1B activation

A

• Released directly after cleavage of the proprotein by caspase 1 (inflammasome)
• As mentioned above, the best characterized inflammasome is the NLRP3 (activated by ATP, MSU, CPPD, amyloid-B, sphingosine)…. however there are others formed from other PRRs:
− NLRC4 (activated by flagellin)
− AIM2 (ds DNA sensing)
• After caspase 1 activation, IL-1b is rapidly secreted from the cell.

Inflammasome formation can be visualized in the lab:
• Prepare a virus that expresses the ASC adaptor protein fused to a fluorescent protein mCherry
• NLRP3 binds to its PAMP/DAMP, and this nucleates a reaction with ASC.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the conventional pathway of protein secretion

A

• Proteins are co- or post-translationally translocated to the ER
− signal sequence at the N-terminus of the newly generated peptide is recognized by the signal recognition particle on the ribosome.
− The SRP bound to the ribosome and nascent protein chain then binds to the SRP receptor on the ER membrane
− Peptide chain is translocated through the protein conducting channel formed by sec61a and sec61y subunits into the ER lumen.
• One in the ER lumen, the signal is removed from the nascent peptide chain, assumes its correctly folded state, and accumulates at the ER exit site by binding to the COPII complex.
• The COPII complex facilitates budding of vesicles that then fuse with the golgi, where they undergo post-translational modifications before they are excytosed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the rescue and redirect model of IL-1 secretion.

A

• IL-1B is transplated on free polyribosomes associated with the cytoskeleton
• The vast majority localizes to the cytosol, however a fraction of cellular IL-B is targeted to lysosomes for degradation. This fraction can be rescued by triggering lysosome exocytosis and thus secretion if IL-1B
• Suggested autophagy may be the method that they get sequestered into vesicles → during autophagy, damaged organelles or proteins in the cytosol become enclosed in an autophagosome which fuses with lysosome, resulting in degradation of the contents.
− Indeed, LPS treatment of macrophages induces the recruitment of IL-1B to autophagosomes.
− When autophagy is inhibited, IL-1B is secreted; when activated, it is degraded.
− Thus, a fraction of IL-1B targeted for degradation can be ‘rescued’ and ‘redirected’ to the extracellular environment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the protected release model of IL-1B secretion.

A

Microvesicles:
• Involves the shedding of IL-1B containing microvesicles that bud from the plasma membrane
• Originally observed in THP-1 cells, whereby shedding is preceded by flip of the lipid phosphatidylserine to the outer leaflet of the plasma membrane, and in astrocytes recquires the activation of sphingomyelinase.
• The IL-1B in shed microvesicles is bioactive, and may be released following contact with IL-1 receptor expressing cells
• ATP stimulation of these microvesicles can also induce the release of their contents

Exosomes:
• IL-1B can be packaged into small exosomes.
• Multiple exosomes are secreted within multi-vesicular bodies
• The secretion of these exosomes in LPS-stimulated macrophages is dependent upon ASC and NLRP3, but independent of caspase 1.

→ That fact that much of IL-1B secreted from cells is directly available, and the fact IL-1B has a short halflife in plasma, suggests that protected IL-1B is destined for signaling at sites distal to the local inflammatory lesion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the terminal release model of IL-1B secretion

A
  • A consequence of NLRC4-dependent caspase 1 activation in macrophages is a rapid cell death called pyroptosis. This is a pro-inflammatory form of cell death that causes the macrophage to kill itself and release pro-inflammatory cytokines.
  • This doesn’t depend on IL-1B processing (although it does occur) – so seems to serve primarily to eliminate the intracellular niche required for pathogen growth.
  • Occurs following the caspase-1 dependent formation of pores in the plasma membrane → causes the dissipation of ionic gradients and osmotic lysis of the cell..
  • In addition to pyroptosis, ATP activation of NLRP3 has been shown to cause macrophages to round up and bleb, closely followed by the cytolytic marker LDH → raising the suggestion that IL-1B release signals a commitment to cell death.
17
Q

What is the basic evidence that suggests the inflammasomes are involved in brain injury?

A

• An expression profile of inflammasome components showed that the apparatus required for NLRP1 an NLRP3 inflammasomes is present consitutively within the brain.
− NLRP1 found constitutively in neurons → activated by anthrax toxin and MDP, a motif carried by peptidoglycan.
➢ Administration of an anti-ASC antibody in rats after injury to the spinal cord reduced neuronal injury and improved functional outcome
➢ In addition, neutralization of NLRP1 in a mouse model of thromboembolic stroke resulted in reduced levels of active caspase 1 and mature IL-B, although only a small (18%), non-significant reduction in infarct size.
− NLRP3 expressed by microglia → activated by a diverse array of PAMPs and DAMPs
➢ Given the heterogenetic of NLRP3 activating ligands, it is reasoned that they do not act as direct ligands, but converge upon a common endogenous signal such as the generation of ROS.
➢ Given there will be tissue necrosis after brain injury, and NLRP3 has become well established as the sensor for necrotic cells, reasonable to suggest NLRP3 will contribute to the inflammation.
➢ In a mouse model of focal cerebral ischaemia, cathepsin B co-localised with caspase 1, and the cathepsin B inhibitor inhibited caspase 1 activation, consistent with the involvement of the NLRP3 inflammasome.
➢ Amyloid beta (main constituent of plaques in the brains of patients with AD) is known to activate the NLRP3 inflammasome in cultured mouse microglia.

18
Q

What is the evidence that suggested the NLRP3 inflammasome has a role in the pathology of Alzheimers?

A

Heneka et al: NLRP3 inflammasome contributes to the worsening of AD
• Used APP/PS1 transgenic mice → over express the two proteins known to be causative in human AD. The majority of early-onset AD patients have mutated presenilin or APP genes.

Protective effects of NLRP3 deficiency in APP/PS1 mice:
• Performed western blots against the p10 subunit of caspase 1 in brains of patients that died of AD – these all had more activated caspase than the controls (do still see some in controls, because ageing itself is an inflammatory disease)
• In mice:
− NLRP3 KO → no caspase 1
− APP/PS1 animals → active caspase 1
− Cross NLRP3 KO with APP animals → no caspase 2
− Shows that in these AD animals, you have NLRP3 dependent activation of caspase 1. If you knock NLRP3 out, you don’t get caspase 1 activation even though they have the mutant proteins.
• Translating this data to memory function:
− Used Morris water maze test
− AD mouse cant find the platform, has memory deficit
− NLRP3 KO mouse CAN find the platform
− NLRP3 KO x APP/PS1 mouse CAN find the platform → so the memory deficit of the AD mouse is lost if they have no NLRP3.
➢ This really identifies that NLRP3 mediates inflammation is necessary for the Alzheimers memory lost symptoms.

19
Q

Describe the experiments that showed existing drugs could be re-purposed for the treatment of alzheimers disease.

A

• No drug currently in the clinic targets the inflammasome
• Are drugs that are already in clinical use available to be repurposed and used for something else?
Daniels et al: Fenamate NSADs are NLRP3 inflamamsome inhibitors
• NSAIDs such as ibuprofen don’t have any effect on IL-1B release
• However, fenamte NSAIDs cause a dramatic reduction in IL-1 release
• Fenamates inhibit ASC spec formation – NLRP3 nucleates ASC so caspase 1 can be oligomerised. Fenamates inhibit this by blocking an ion channel in the membrane.

In vivo proof of concept:
• Fine showing that fenamates block the inflammasome in vitro, but does this work in vivo?
• Protocol:
1. Give drug prophylactically
2. Inject oligomers of amyloid beta into the cerebral ventricles
3. At 4 days, do behavior novel object recognition test
4. Stop fiving animals drug at 13 days
5. Do another test at day 14
6. Leave them drug free for 35 days
7. Do another test at day 35
• Giving amyloid beta induces memory loss – they don’t have increased time investigating a new object
• But in those animals given mefenamic acid, they investigate the novel object as much as the controls → Fenamates inhibit amyloid beta induced memory deficits.
• Animals were still protected 35 days after drug removal

• When submitted to a paper, they wanted to see them give this drug as treatment, not prophylactically.
1. Took 13 month old animals that already had memory deficit
2. Infuse with drug for a month
3. Memory test after a month
• They had recovered back to the level of the wild type

Summary:
• NLRP3 inflammasome contributes to memory loss in animal models of AD
• Exisiting drugs can be repurposed – saves time and money.

20
Q

What is the evidence of inflammasome involvement in stroke?

A

• Caspase 1 inhibitor shown to reduce lesion volume by 2 thirds.
• In the MCA model of stroke:
− NOD2 used as negative control – PRR that doesn’t form the inflammasome. KO no differnent to wildtype.
− ASC knockout gives more than 50% protection – so caspase 1 and inflammasome definitely involved, however…
− NLRP3 knockout shows no different to wildtype – so must be a different inflammasome!

→ AIM2 responds to dsDNA – could be involved, as this would be released during necrosis.
→ NLRC4 responds to pathogens, so less likely to be involved, but still could be.
− Both AIM2 and NLRC4 knockouts were protective!
− NLRC4 was predicted to be less important due to activation by pathgoens. However, there is literature coming through that the gut microbiota can become systemic aftery injury, and may be involved in stroke:
− Intestinal immune system is the largest component
− Altered systemic immunity after brain lesion may affect microbiota, leading to the traslocation of bacteria through mucosal barriers, further impacting the immune system and providing co-stimulation in immune-brain cell interactions.
− Direct impact of brain lesions on the microbiota is also expected via the sympathetic nervous system.
− GUTSTROKE study in Charite University, Berlin suggests microbiome impacts on outcome after CNS lesion via effects on the immune system, direct humoral signaling and effects on the enteral nervous system.

21
Q

What is an important consideration with using animal models of acute brain injury?

A

• Although experimental models of acute brain injury are sterile, this is rarely the case clinically where patients often present with co-morbidities
• Thus, inflammatory status within an individual suffering brain injury will often be elevated due to infection or chronic inflammatory disease.
• To mirror this, comorbid animal models of stroke are being developed
• In the two major risk factors for stroke:
− Obesity & T2DM → NLRP3 expression correlates with inflammation and insulin resistance. Obseity induced inflammation reduced in NLRP3 KO mice
− Atherosclerosis → cholesterol crystals activate NLRP3. Mice fed high fat diets have reduced atherosclerotic lesions with NLRP3 KO compared to wildtype

→ Therefore, inflammasomes not only contribute directly to brain injury, but will also contribute to the factors associated with increased risk.

22
Q

How can IL-1 be targeted as a treatment for brain disease?

A

• Stroke remains the commonset cause of adult neurological disability in the Western World
• In ischaemic stroke, therapeutic strategies aimed primarily at reperfusion, with thrombolysis in selected cases and aspirin.
• In stroke due to haemorrhage, there is no specific treatment apart from surgery in a select group of patients, reversal of bleeding diathesis and prevention of re-bleeding together with supportive care.
• Blocking IL-1 is attractive because it could reduce levels of inflammation that might pre-dispose to disease, or acute inhibition at the earliest possible time after injury may reduce inflammation-induced damage.
− Biological agents that target IL-1, such as IL-1Ra (anakinra) and specific monoclonal antibodys such as canakinumab (anti-IL1B) are used for management of several anti-inflammatory disorders.
− IL-1RA is neuroprotective in experimental models of acute brain injury and has shown promise in early results of clinical trials.
− IL-1B antibody protective in a rat model of stroke
− In several experimental models of acute brain injury, anti-ASC has shown protective effects
− Specific caspase 1 inhibitors are protective
− The T2DM drug glyburide inhibits NLRP3 and is protective in rat models of stroke